The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary safety results of an ongoing phase I/II clinical study of MGN1601, a tumor vaccine comprising allogeneic, gene-modified, and irradiated tumor cells in combination with an immunomodulator in patients with metastatic renal cell carcinoma (ASET study).
Marina Tschaika
No relevant relationships to disclose
Steffen Weikert
No relevant relationships to disclose
Viktor Gruenwald
No relevant relationships to disclose
Ingo Schmidt-Wolf
No relevant relationships to disclose
Matthias Schroff
No relevant relationships to disclose
Burghardt Wittig
No relevant relationships to disclose
Manuel Schmidt
No relevant relationships to disclose